Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMD-102 in Hepatocellular Carcinoma and Other Advanced Solid Tumors
NCT07636785Phase 2Recruiting
- Sponsor
- VM Discovery
- Start
- Jul 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VMD-102 in hepatocellular carcinoma (HCC), Uveal melanoma (UM), renal cell carcinoma (RCC) and 2 more, sponsored by VM Discovery. Primary endpoints: Number and severity of treatment-emergent adverse events at 21 days, Recommended Phase 2 dose at 21 days and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
VMD-102
03
Conditions
hepatocellular carcinoma (HCC)Uveal melanoma (UM)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07636785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636785.